MetLife Investment Management’s Abeona Therapeutics ABEO Stock Holding History

MetLife Investment Management’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$106K	Sell	23,772 -166	-0.7%	-$830	﹤0.01%	2510
2025 Q4	$126K	Sell	23,938 -2,688	-10%	-$13.5K	﹤0.01%	2496
2025 Q3	$141K	Hold	26,626	–	–	﹤0.01%	2496
2025 Q2	$151K	Buy	+26,626	New	+$152K	﹤0.01%	2333
2019 Q3	–	Sell	-503	Closed	-$60.1K	–	2330
2019 Q2	$60.1K	Hold	503	–	–	﹤0.01%	2410
2019 Q1	$92.5K	Hold	503	–	–	﹤0.01%	2316
2018 Q4	$89.8K	Hold	503	–	–	﹤0.01%	2317
2018 Q3	$161K	Sell	503 -270	-35%	-$95.8K	﹤0.01%	2200
2018 Q2	$309K	Buy	773 +283	+58%	+$124K	﹤0.01%	1701
2018 Q1	$176K	Hold	490	–	–	﹤0.01%	1950
2017 Q4	$194K	Buy	+490	New	+$203K	﹤0.01%	1942

Other funds holding ABEO

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MetLife Investment Management's ABEO Position: Q1 2026 in Review

MetLife Investment Management reduced its Abeona Therapeutics (ABEO) stake by 0.69% in Q1 2026, selling an estimated $830 and leaving 23,772 shares worth $106K. The position accounts for ﹤0.01% of the portfolio, ranked #2510.

MetLife Investment Management first reported a position in ABEO in Q4 2017 and has held it in 11 quarters since. The position peaked at $309K in Q2 2018. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

MetLife Investment Management held 23,772 shares of Abeona Therapeutics worth $106K as of Q1 2026.
MetLife Investment Management sold 166 Abeona Therapeutics shares in Q1 2026, an estimated $830.
Abeona Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2510 holding.
MetLife Investment Management first reported a position in Abeona Therapeutics in Q4 2017 and has held it in 11 quarters since.
MetLife Investment Management's Abeona Therapeutics position peaked at $309K in Q2 2018.
108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.